Arcutis Biotherapeutics Reports Q3 Revenue Beat Amid GAAP EPS Miss
Arcutis Biotherapeutics (ARQT) reported third-quarter financial results characterized by a significant divergence between top-line growth and bottom-line profitability. The company achieved revenue of $143.9 million, representing a 45.1% increase year-over-year and exceeding analyst expectations by $1.31 million. Despite the strong revenue performance, Arcutis reported GAAP earnings per share (EPS) of $0.06, which missed consensus estimates by $0.10. This discrepancy highlights ongoing challenges in translating rapid commercial growth into immediate GAAP profitability as the company continues to scale its operations.
Tickers: $ARQT